The launch of GSK’s respiratory syncytial virus vaccine, Arexvy, has exceeded all expectations, earning £709m ($806m) in the third quarter, and establishing an early lead over Pfizer’s rival offering, Abrysvo.
A Stellar Launch For RSV Vaccine Arexvy Lifts GSK
GSK has enjoyed a better-than-expected launch for its RSV vaccine, but emphasized that it was still early days, and the firm is not altering its £3bn peak annual sales forecast for the product.

More from Earnings
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
More from Business
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.